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ROS influence normal hematopoietic 
stem cell (HSC) development
A series of landmark studies of HSC bi-
ology in Drosophila melanogaster and in 
mammalian systems revealed that ROS 
are critical in regulating the balance be-
tween HSC self-renewal and differen-
tiation (Ito et al., 2006; Tothova et al., 
2007;  Owusu-Ansah  and  Banerjee, 
2009; Fig. 1). The initial realization of 
the ability of elevated levels of ROS to 
limit HSC self-renewal came from the 
observation that mice lacking the ataxia 
telangiectasia mutated (Atm) gene de-
velop early-onset bone marrow failure 
that  correlated  with  increased  ROS 
abundance (Ito et al., 2004). This im-
pairment in HSC self-renewal resulted 
from  ROS-induced  activation  of  the 
p38  MAPK  signaling  pathway  (Ito   
et al., 2006). Later, it was shown that 
regulation of ROS levels in the quies-
cent HSC compartment was mediated 
by the forkhead O (FoxO) family of   
transcription factors (Tothova et al.,   
2007). Mice with Mx-Cre recombi-
nase-driven conditional loss of FoxO1, 
FoxO3, and FoxO4 in the hematopoi-
etic  system  exhibited  a  marked  re-
duction in HSC numbers, as well as 
reduced functional evidence of HSCs 
in competitive and noncompetitive re-
constitution  assays.  However,  during 
the  transition  from  HSC  to  myeloid 
progenitors, ROS levels increase in a 
manner independent of FoxO activity 
(Tothova  et  al.,  2007).  In  fact,  it   
is  speculated  that  increased  levels  of 
ROS may even act as an intracellular 
trigger  for  HSC  differentiation  to   
myeloid  lineage  fates  (Tothova  and 
Gilliland, 2007). These findings from 
vertebrates were recently reinforced in 
studies in D. melanogaster that revealed 
that  ROS  accumulates  at  a  specific 
stage of hematopoietic development to 
trigger myeloid progenitor differentia-
tion  from  HSCs  (Owusu-Ansah  and 
Banerjee, 2009).
The  results  of  these  studies  lend 
credence to the possibility that LSCs 
might  be  susceptible  to  elevations  in 
ROS  abundance,  and  that  elevated 
ROS levels might even trigger differ-
entiation  of  leukemic  blasts.  Prior   
reports  that  the  naturally  occurring 
molecule parthenolide may specifically 
target LSCs by inducing ROS further 
support this idea (Guzman et al., 2005). 
In  addition,  the  observation  that  the 
serine-threonine kinase Akt is consti-
tutively  activated  in  the  majority  of 
primary  AML  samples  suggests  that 
some inhibition of FoxO function and 
increase in ROS levels are to be ex-
pected in AML samples relative to nor-
mal HSCs (Xu et al., 2003; Tothova 
and Gilliland, 2007).
Iron chelation therapy elevates ROS 
and induces AML differentiation
In this issue, Callens et al. report the 
effect of iron chelation therapy in AML 
cell lines and primary patient samples 
(Callens et al., 2010). They found that 
iron deprivation therapy, whether in-
duced by iron chelators or by treatment 
with  a  transferrin  receptor–specific   
antibody, promotes mature monocytic 
differentiation  of  leukemic  cell  lines, 
cultured leukemic blasts from patient 
samples, and normal HSCs from cord 
blood. Although iron deprivation may 
decrease ROS by decreasing substrates 
for the Fenton reaction, iron chelators 
also induce generation of ROS (Chaston 
et al., 2004). Indeed, the authors found 
that iron deprivation by deferasirox re-
sulted  in  dose  and  time-dependent 
ROS formation. The investigators then 
used antioxidants to show that the pro-
duction  of  ROS  by  iron  chelating 
treatments was specifically responsible 
for monocytic differentiation of leuke-
mia. Consistent with prior reports that 
activation of c-Jun N-terminal kinase 
(Jnk)  is  downstream  of  the  oxidant 
stress  response  (Owusu-Ansah  and   
Banerjee,  2009),  iron  deprivation– 
induced differentiation was dependent 
on  Jnk  activation.  The  authors  also 
compared  the  gene  expression  signa-
ture induced by iron chelation in the 
HL60 cell line with that induced by 
differentiation  caused  by  vitamin  D3 
treatment. Interestingly, a surprisingly 
high number of genes were up-regulated 
by  both  treatments.  Moreover,  iron 
chelation  and  vitamin  D3  therapies 
synergized in inducing monocytic dif-
ferentiation  of  leukemic  cell  lines,   
suggesting a possible shared mechanism 
of action.
Acute leukemias are clonal disorders of hematopoiesis wherein a leukemic 
stem cell (LSC) acquires mutations that confer the capacity for unlimited 
self-renewal, impaired hematopoietic differentiation, and enhanced proliferation 
to the leukemic clone. Many recent advances in understanding the biology of 
leukemia have come from studies defining specific genetic and epigenetic 
abnormalities in leukemic cells. Three recent articles, however, further  
our understanding of leukemia biology by elucidating specific  
abnormalities in metabolic pathways in leukemic hematopoiesis. These  
studies potentially converge on the concept that modulation of reactive 
oxygen species (ROS) abundance may influence the pathogenesis and  
treatment of acute myeloid leukemia (AML).
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et al., 2009; Mardis et al., 2009; Yan   
et al., 2009; Zhao et al., 2009). In addi-
tion,  mutations  in  IDH2,  the  mito-
chondrial  homologue  of  IDH1,  were 
identified  in  brain  tumors  expressing 
wild-type  IDH1,  but  had  not  been 
identified  in  AML  patients.  IDH1   
mutations  are  associated  with  a  neo-
morphic enzymatic activity leading to   
the  production  of  the  metabolite   
2-hydroxyglutarate (2-HG; Dang et al., 
2009). In a recent issue of JEM, Gross   
et al. (2010) screened AML samples   
for  2-HG  production  using  liquid- 
chromatography mass-spectroscopy and 
found several AML tumor samples with 
elevated levels of 2-HG. Interestingly, 
although  some  samples  with  elevated   
2-HG  abundance  harbored  mutations 
in IDH1, a subset of samples with mark-
edly  elevated  2-HG  levels  expressed 
wild-type  IDH1.  They  then  demon-
strated that these latter samples had mu-
tations at R172 of IDH2, a mutation 
previously  identified  in  patients  with 
central nervous system tumors. More-
over, recombinant mutant IDH2, but 
not wild-type IDH2, resulted in 2-HG 
accumulation. These data demonstrate 
that  IDH2  mutations  occur  in  AML   
patients, and are associated with eleva-
tions  in  2-HG  similar  to  those  seen   
in IDH1 mutant AML and glioma pa-
tient samples.
In a concurrent study, Ward et al. 
(2010) screened a large cohort of AML 
patients  for  2-HG  production,  and 
identified IDH2 mutations in patients 
expressing wild-type IDH1 but show-
ing elevated 2-HG levels. In addition, 
Ward et al. (2010) identified a novel 
mutation  in  IDH2  at  residue  R140 
(R140Q), which was not seen previ-
ously in glioblastoma or AML patients, 
and which results in accumulation of   
2-HG. The IDH2 R140Q mutation is 
more  common  in  AML  than  IDH1 
mutations  or  IDH2  R172  mutations, 
suggesting  that  different  mutations  in 
IDH1 and IDH2 occur at different fre-
quencies in different tumor types. They 
also performed structural modeling to 
show that these three residues in IDH1 
and IDH2 that are mutated in AML pa-
tients are likely critical in stabilizing the 
interaction between IDH1 and IDH2 
IDH1/2 mutations result in increased 
ROS and hypoxia-inducible factor  
I (HIF-1)
The  identification  of  ROS  levels  as 
critical  regulators  of  HSC  quiescence 
and differentiation also led to the real-
ization that the heterodimeric transcrip-
tion  factor  HIF-1  is  responsible  for 
mediating many of the effects of hy-
poxia on HSCs (Adelman et al., 1999, 
2000).  The  relative  hypoxia  in  the 
HSC niche leads to increased stability 
of HIF-1 and up-regulation of HIF- 
1–mediated transcriptional targets im-
portant  for  maintenance  of  HSC 
quiescence, such as vascular endothelial 
growth factor and FoxO (Eliasson and 
Jönsson, 2010). Perhaps, then, it is not 
surprising that mutations in metabolic 
enzymes  affecting  ROS  and  HIF-1 
levels are now being described in AML 
(Mardis et al., 2009; Gross et al., 2010; 
Ward et al., 2010).
Genome-wide  sequencing  studies 
identified somatic mutations in isocitrate 
dehydrogenase 1 (IDH1) in central ner-
vous  system  tumors  and  in  AML   
patients, but not in other human malig-
nancies  (Parsons  et  al.,  2008;  Dang   
The  authors  conclude  their  study 
with a description of a case report of an 
elderly patient with AML treated with 
the oral iron chelator deferasirox (1 g/d) 
and  the  vitamin  D3  metabolite  25- 
hydroxycholecalciferol  (4,000  IU/d). 
Treatment was associated with a de-
crease in blast counts and an increase in 
the production of differentiated mono-
cytes. Although this single case report 
needs to be extended to formal clinical 
trials, it does suggest that the effects 
seen in cell lines are also seen in vivo. 
Many  questions  remain,  including 
whether this is the only mechanism by 
which  iron  chelation  therapy  induces 
LSC differentiation, whether the effects 
of modulating ROS levels are specific 
to LSCs or also have negative effects on 
normal HSCs, and whether there are 
more specific agents that can be used   
to modulate ROS levels without the 
pleiotropic  effects  of  iron  chelation 
agents.  However,  these  data  suggest 
that  the  novel  therapeutic  strategy  of 
modulating ROS levels in LSCs through 
the use of iron-chelating agents and/ 
or vitamin D can induce LSC differ-
entiation (Fig. 1).
Figure 1.  ROS, IDH1/2 mutations, and iron chelation therapy in normal and leukemic  
hematopoiesis. In normal hematopoiesis, the HSC resides in a niche characterized by a low partial 
pressure of oxygen (PO2) and elevated HIF1-. Myeloid differentiation of HSCs is triggered, in part, 
by increased PO2 and increased ROS. A leukemia is thought to be a newly formed hematopoietic 
tissue initiated by a few LSCs. LSCs derived from either normal HSCs or more restricted multipotent 
progenitors (MPPs) as a result of genetic abnormalities. LSCs from AML patients may differentiate in 
response to a temporary increase in ROS caused by iron chelators. At the same time, mutations in 
the metabolic enzymes IDH1/2 observed in some AML patients may result in increased ROS and  
HIF-1. Mutations impair the normal enzymatic activity of IDH1/2, which is to create NAD(P)H and  
-KG, and increase production of the oncometabolite 2-HG. 2-HG is thought to increase ROS con-
centrations. In addition, decreased abundance of -KG results in reduced -KG–mediated inhibition 
of proline hydroxylases; this facilitates increased HIF-1 stability.JEM VOL. 207, April 12, 2010 679
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required  to  delineate  the  mutational 
spectrum, prognostic effects, and asso-
ciated  clinical  features  of  IDH1/2   
mutations in AML. However, the ge-
netic data from these studies suggest a   
potential  novel  pathway  to  leukemic   
transformation  for  IDH1/2  mutant 
hematopoietic  progenitors.  Notably,   
recent  studies  suggest  that  IDH1/2 
mutations can be found in AML trans-
formed from myeloproliferative neo-
plasms, suggesting that these mutations 
can promote transformation of a pre-
leukemic clone (Green and Beer, 2010; 
Abdel-Wahab et al., 2010).
In addition to genomic correlative 
studies of IDH1/2 mutations in hema-
tologic  malignancy  samples,  experi-
mental studies will elucidate the specific 
role  of  these  mutations  in  leukemic 
transformation.  Specifically,  although 
the novel biochemical effects of these 
mutant  alleles  have  been  extensively 
described in recent studies, the mecha-
nisms by which these mutations confer 
a selective advantage to the malignant 
clone are not yet understood. Examina-
tion of the effects of IDH1/2 mutant 
alleles  on  hematopoietic  ROS  and 
HIF1- levels, and on self-renewal, dif-
ferentiation, and proliferation, will be 
critical. Likewise, study of the effects of 
expression  of  IDH1/2  mutant  alleles   
in  the  hematopoietic  compartment   
will likely elucidate the mechanisms 
by  which  these  alleles  contribute  to 
transformation. Nevertheless, taken to-
gether, these three new studies highlight 
the importance of metabolic pathways 
to the pathogenesis of AML, and sug-
gest the possibility that elevated ROS 
levels  in  AML  cells  might  represent   
an  “Achilles  heel”  that  can  be  used   
to specifically target AML cells with 
novel therapies.
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evaluate effects of 2-HG on ROS levels 
in tissues other than neuronal cells has 
yet to be performed. Moreover, studies 
to  compare  ROS  levels  in  primary 
AML blasts with and without IDH1/2 
mutations will be necessary to establish 
a link between IDH1/2 mutations and 
elevation in ROS in LSCs and in the 
bulk leukemic clone.
All  genomic  data  published  thus   
far  has  indicated  that  mutations  in 
IDH1/2 occur as heterozygous mis-
sense  mutations  (Dang  et  al.,  2009; 
Mardis et al., 2009; Yan et al., 2009; 
Zhao et al., 2009; Gross et al., 2010; 
Ward et al., 2010). The fact that ho-
mozygous missense mutations have not 
been  identified  is  consistent  with  the 
finding  that  IDH1/2  missense  muta-
tions result in a gain of function. More-
over, NAPDH produced by wild-type 
IDH1  enzymatic  activity  is  a  critical 
substrate for the neomorphic enzymatic 
activity of the mutant IDH1 (Ward et al., 
2010). In addition, siRNA-mediated 
depletion of wild-type IDH1 or IDH2 
is lethal to cells in culture, suggesting 
that the wild-type allele must be re-
tained in IDH1/2 mutant cancer cells.
The  overall  effect  of  concomitant 
increased ROS and HIF-1 activity in 
HSCs could affect quiescence and dif-
ferentiation in a manner that promotes 
hematopoietic transformation (Fig. 1). 
The effect of metabolic derangements 
induced by IDH1/2 mutations in the 
HSC might also be influenced by the 
presence of other oncogenic mutations 
seen in AML. Of note, mutational anal-
ysis of an AML cohort for IDH1 R132, 
IDH2 R172, and IDH2 R140 muta-
tions found IDH1 and IDH2 mutations 
in 8 and 15% of AML patients, respec-
tively, demonstrating these are relatively 
common  mutations  in  AML.  More-
over, Gross et al. (2010) and Ward et al. 
(2010)  suggest  that  IDH1/2  mutant 
AML frequently occur in normal karyo-
type AML without other known onco-
genic  mutations.  These  results  are 
corroborated in at least one other larger 
clinical  study  of  IDH1  mutations  in 
AML  samples  (Chou  et  al.,  2010). 
Clearly, larger studies with more clini-
cal  samples  including  both  IDH1   
and IDH2 mutational analysis will be   
and their physiological substrate, isocit-
rate. Lastly, they performed cell culture 
studies to demonstrate that expression 
of IDH1 or IDH2 mutants results in 
increased  -ketoglutarate  [-KG]– 
dependent production of 2-HG.
Underlying  this  discovery  of  the 
production of 2-HG by mutant IDH1/2 
enzymes  in  AML  is  the  finding  that 
mutant IDH1/2 enzymes also lead to 
consumption of NADPH (Dang et al., 
2009).  Normally,  when  IDH1/2  en-
zymes convert isocitrate to -KG, this 
leads  to  the  concurrent  reduction  of 
NAD(P)+ to NADPH. In fact, IDH1   
is normally responsible for generating   
a  significant  proportion  of  cellular 
NADPH  (Kil  et  al.,  2006,  2007). 
NADPH is critical for several cellular 
metabolic processes, including synthesis 
of  glutathione,  which  protects  cells 
from oxidative stress. Thus, it is plausi-
ble that mutations that result in impair-
ment of normal IDH1/2 function may 
deplete cellular NADPH. At the same 
time that IDH1/2 mutations may re-
duce levels of NADPH, the metabolite 
created by the neomorphic function of 
mutant IDH1/2, 2-HG, is thought to 
increase  levels  of  intracellular  ROS 
(Kölker et al., 2002; Latini et al., 2003). 
As IDH1/2 mutations result in deple-
tion of NADPH and increased ROS, 
levels of -KG are also decreased by 
IDH1/2 mutations. Because -KG nor-
mally serves to activate proline hydrox-
ylases that inactivate HIF-1, depletion 
of -KG results in increased levels of 
HIF-1  and  its  associated  targets 
(MacKenzie et al., 2007). Thus, the ab-
rogation  of  the  normal  enzymatic   
activity of IDH1/2, together with the 
acquisition of the ability to produce   
2-HG, increases ROS abundance and 
HIF-1 stability.
The evidence linking accumulation 
of 2-HG to elevations in ROS comes 
from studies of primary neuronal cul-
tures  exposed  to  2-HG  in  vitro  and 
brain  tissue  from  rats  treated  with   
2-HG in vivo. In both settings, 2-HG 
treatment elicited ROS as measured by 
oxidant-sensitive dyes, lipid peroxida-
tion, and/or levels of enzymatic oxida-
tive stress defenses (Kölker et al., 2002; 
Latini  et  al.,  2003).  Further  work  to 680 Metabolism and the leukemic stem cell | Abdel-Wahab and Levine
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